Edition:
United States

Lennox International Inc (LII.N)

LII.N on New York Stock Exchange

205.22USD
4:02pm EDT
Change (% chg)

$-0.62 (-0.30%)
Prev Close
$205.84
Open
$205.82
Day's High
$206.70
Day's Low
$204.00
Volume
64,738
Avg. Vol
94,520
52-wk High
$222.31
52-wk Low
$160.18

Chart for

About

Lennox International Inc. is a provider of climate control solutions. The Company designs, manufactures and markets a range of products for the heating, ventilation, air conditioning and refrigeration (HVACR) markets. It operates through three segments: Residential Heating & Cooling; Commercial Heating & Cooling, and Refrigerati... (more)

Overall

Beta: 1.20
Market Cap(Mil.): $8,489.41
Shares Outstanding(Mil.): 41.24
Dividend: 0.64
Yield (%): 1.24

Financials

  LII.N Industry Sector
P/E (TTM): 26.26 28.40 22.81
EPS (TTM): 7.84 -- --
ROI: 29.19 11.17 7.97
ROE: -- 12.98 15.35

BRIEF-Lennox International Increases Dividend 25 Percent

* SETS QUARTERLY CASH DIVIDEND OF $0.64PER SHARE Source text for Eikon: Further company coverage:

May 15 2018

BRIEF-Lennox International Reports Q1 Adjusted Earnings Per Share $1.13 From Continuing Operations

* LENNOX INTERNATIONAL REPORTS RECORD FIRST-QUARTER REVENUE AND PROFIT

Apr 23 2018

BRIEF-Lennox International Says CEO's 2017 Compensation Was $11.45 Mln

* LENNOX INTERNATIONAL INC SAYS CEO TODD M. BLUEDORN'S 2017 TOTAL COMPENSATION WAS $11.45 MILLION VERSUS $10 MILLION IN 2016 – SEC FILING‍​ Source: (https://bit.ly/2GUhs6F) Further company coverage:

Apr 05 2018

BRIEF-Lennox International Q4 EPS $1.02 From Continuing Operations

* LENNOX INTERNATIONAL REPORTS RECORD FOURTH QUARTER MARGIN AND PROFIT TO CAP RECORD YEAR AND RAISES 2018 EPS GUIDANCE FOR U.S. TAX LEGISLATION

Feb 06 2018

BRIEF-Ovid Therapeutics Announces TAK-935/OV935 Granted Orphan Drug Designation By U.S. FDA For Treatment Of Lennox-Gastaut Syndrome

* OVID THERAPEUTICS ANNOUNCES TAK-935/OV935 GRANTED ORPHAN DRUG DESIGNATION BY U.S. FDA FOR TREATMENT OF LENNOX-GASTAUT SYNDROME

Dec 20 2017

BRIEF-Lennox International Sees Fy18 Revenue Up 3 To 7 Percent

* REAFFIRMS FY 2017 ADJUSTED EARNINGS PER SHARE VIEW $7.75 TO $8.05 FROM CONTINUING OPERATIONS

Dec 13 2017

Earnings vs. Estimates